These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 27842896

  • 1. Kinesin Family Member 11 mRNA Expression Predicts Prostate Cancer Aggressiveness.
    Piao XM, Byun YJ, Jeong P, Ha YS, Yoo ES, Yun SJ, Kim WJ.
    Clin Genitourin Cancer; 2017 Aug; 15(4):450-454. PubMed ID: 27842896
    [Abstract] [Full Text] [Related]

  • 2. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
    Zidan HE, Abdul-Maksoud RS, Elsayed WSH, Desoky EAM.
    IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics.
    Kim EA, Kim YH, Kang HW, Yoon HY, Kim WT, Kim YJ, Yun SJ, Moon SK, Choi YH, Kim IY, Lee SC, Kim WJ.
    J Korean Med Sci; 2015 Jul; 30(7):937-42. PubMed ID: 26130958
    [Abstract] [Full Text] [Related]

  • 8. Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.
    Zhang YX, Wang L, Ji PY, Zhao GG, Zhong GP, Wang ZP.
    Arch Med Res; 2013 May; 44(4):259-65. PubMed ID: 23707648
    [Abstract] [Full Text] [Related]

  • 9. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
    Leidinger P, Hart M, Backes C, Rheinheimer S, Keck B, Wullich B, Keller A, Meese E.
    Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
    [Abstract] [Full Text] [Related]

  • 10. Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level.
    Izumi K, Lin WJ, Miyamoto H, Huang CK, Maolake A, Kitagawa Y, Kadono Y, Konaka H, Mizokami A, Namiki M.
    J Cancer Res Clin Oncol; 2014 Aug; 140(8):1413-9. PubMed ID: 24747988
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease.
    Christoph F, König F, Lebentrau S, Jandrig B, Krause H, Strenziok R, Schostak M.
    World J Urol; 2018 Feb; 36(2):187-192. PubMed ID: 29204705
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. MMP26: A potential biomarker for prostate cancer.
    Cheng T, Li F, Wei R, Lv MQ, Zhou Y, Dai Y, Yuan Y, Jiang GY, Ma D, Gao QL.
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):891-894. PubMed ID: 29270749
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
    Tilli TM, Thuler LC, Matos AR, Coutinho-Camillo CM, Soares FA, da Silva EA, Neves AF, Goulart LR, Gimba ER.
    Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.